Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFQCB1)

Drug Name

Dicumarol Drug Info

Synonyms

Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3′-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin

Indication

Disease Entry	ICD 11	Status	REF
Bleeding disorder	GA20-GA21	Approved	[1]
Myocardial infarction	BA41-BA43	Approved	[2]
Thrombosis	DB61-GB90	Approved	[1]
Intracranial embolism	8B22.1	Investigative	[2]
Venous thromboembolism	BD72	Investigative	[2]

Therapeutic Class

Anticoagulants

Cross-matching ID

PubChem CID: 54676038
ChEBI ID: CHEBI:4513
CAS Number: CAS 66-76-2
TTD Drug ID: DMFQCB1
INTEDE Drug ID: DR1746

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vitamin K epoxide reductase complex 1 (VKORC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[12]
Acenocoumarol	DMH75KV	Thrombosis	DB61-GB90	Approved	[13]
Phenprocoumon	DMDO279	Myocardial infarction	BA41-BA43	Approved	[12]
Phenindione	DM2PYNR	Coagulation defect	3B10.0	Approved	[12]
Tecarfarin	DMTCR2O	Cerebrovascular ischaemia	8B1Z	Phase 3	[14]
------------------------------------------------------------------------------------

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[15]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[16]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[17]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[18]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[19]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[18]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[20]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[21]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[25]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[26]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[27]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[28]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[29]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[30]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[31]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[32]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[33]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[34]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[35]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[36]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[37]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[39]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[40]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[41]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[42]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[43]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[45]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[46]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[47]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[48]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[49]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[50]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[51]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[54]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[55]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[56]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[57]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[58]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[59]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[60]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[61]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[62]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[63]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Mitogen-activated protein kinase 10 (MAPK10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Sorbitol	DMAN0DE	Constipation	DD91.1	Approved	[8]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[66]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[67]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[68]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[69]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[70]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[8]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Catalase (CAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Haloperidol	DM96SE0	Delirium		Approved	[45]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[73]
Selenium	DM25CGV	N. A.	N. A.	Approved	[74]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[75]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[76]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[55]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[77]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[78]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[79]
Selenium	DM25CGV	N. A.	N. A.	Approved	[80]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[81]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[31]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[82]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[33]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[84]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vitamin K epoxide reductase complex 1 (VKORC1)	TTEUC8H	VKOR1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)^{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[5]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Drug Response	[6]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[7]
Mitogen-activated protein kinase 10 (MAPK10)	OTC46VX1	MK10_HUMAN	Gene/Protein Processing	[8]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Gene/Protein Processing	[9]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Post-Translational Modifications	[10]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Drug Response	[6]
Vitamin K epoxide reductase complex subunit 1	OTOJNJRD	VKOR1_HUMAN	Gene/Protein Processing	[11]
Vitamin K epoxide reductase complex subunit 1-like protein 1	OT7QSEWT	VKORL_HUMAN	Gene/Protein Processing	[11]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6808).
2	Dicumarol FDA Label
3	Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9.
4	Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015 Apr-Jun;8(2):171-5.
5	Comparison of graphical and computerized methods for calculating binding parameters for two strongly bound drugs to human serum albumin. J Pharm Sci. 1976 Aug;65(8):1182-7. doi: 10.1002/jps.2600650813.
6	Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. J Biol Chem. 2006 Dec 8;281(49):37416-26. doi: 10.1074/jbc.M605063200. Epub 2006 Oct 13.
7	Impairment of antioxidant defenses as a contributor to arsenite-induced cell transformation. Biometals. 2012 Oct;25(5):927-37. doi: 10.1007/s10534-012-9559-1. Epub 2012 Jun 13.
8	Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem. 1999 Oct 29;274(44):31150-4. doi: 10.1074/jbc.274.44.31150.
9	NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact. 2000 Dec 1;129(1-2):99-112.
10	Dicoumarol relieves serum withdrawal-induced G0/1 blockade in HL-60 cells through a superoxide-dependent mechanism. Biochem Pharmacol. 2005 Jun 1;69(11):1613-25.
11	VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. Blood Adv. 2018 Mar 27;2(6):691-702.
12	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
13	Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7.
14	Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74.
15	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
16	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
17	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
18	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
19	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
20	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
21	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
22	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
23	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
24	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
25	Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
26	Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
27	Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
28	Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
29	Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
30	Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
31	P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
32	Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
33	Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
34	Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
35	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
36	Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
37	BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
38	Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
39	Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
40	Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
41	Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
42	HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
43	Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
44	Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
45	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
46	A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
47	The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
48	Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
49	Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
50	Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
51	[Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
52	Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
53	Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
54	p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
55	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
56	Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
57	Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
58	Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
59	Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
60	Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
61	Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
62	Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
63	Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
64	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
65	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
66	Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
67	Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
68	Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
69	Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
70	Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008 Nov;45(4):532-40. doi: 10.1111/j.1600-079X.2008.00641.x.
71	Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
72	Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate. 2000 May 1;43(2):144-9. doi: 10.1002/(sici)1097-0045(20000501)43:2<144::aid-pros9>3.0.co;2-h.
73	Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83. Int J Mol Sci. 2020 Aug 1;21(15):5533. doi: 10.3390/ijms21155533.
74	Selenium deficiency alters epithelial cell morphology and responses to influenza. Free Radic Biol Med. 2007 Jun 15;42(12):1826-37.
75	Hepatocellular peroxisomes in human alcoholic and drug-induced hepatitis: a quantitative study. Hepatology. 1991 Nov;14(5):811-7.
76	Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci. 2004 Aug;254(4):231-5.
77	The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
78	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
79	Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
80	Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
81	Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
82	Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
83	Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
84	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
85	Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
86	Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.